

Molesworth, AM; Andrews, NJ (2006) Variant Creutzfeldt-Jakob disease in the United Kingdom and elsewhere: situation at the end of 2005. Euro surveillance, 11 (1). E060126.4. ISSN 1025-496X

Downloaded from: http://researchonline.lshtm.ac.uk/10748/

DOI:

Usage Guidelines

 $Please \ refer \ to \ usage \ guidelines \ at \ http://researchonline.lshtm.ac.uk/policies.html \ or \ alternatively \ contact \ researchonline@lshtm.ac.uk.$ 

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/

# Europe's journal on infectious disease epidemiology, prevention and control

HOME	ARCHIVES	ABOUT US	EDITORIAL POLICY	FOR AUTHORS	FOR REVIEWERS	LINKS 20-YEAR A	NNIVERSARY		
Search	Home ▶ Euros	urv eillance Wee	ekly Release 2006: Volum	le 11/ Issue 4 ⊩ Article 4					
	4 Baak ta Tabi	o of Contonto					In this issue		
Submit article	Previous	<ul> <li>I Back to Table of Contents</li> <li>I Previous</li> <li>TWEet Next ►</li> </ul>							
RSS Feed							A/H5N1: lessons from Belgium ▶ Clostridium difficile PCR		
Follow us on Twitter	Eurosurve	ribotype 027 outbreaks in the Netherlands: recent surveillance data indicate that outbreaks are not easily controlled but interhospital transmission is limited Urgent action needed to stop							
Subscribe	Articles								
Unsubscribe	Citation style for								
Sontact	situation at the ArticleId=2884								
? Sitemap							spread of hepatitis B and C in Estonian drug users		
Announcements	Variant Cr end of 200	<ul> <li>Variant Creutzfeldt-Jakob disease in the United Kingdom and elsewhere: situation at the end of 2005</li> <li>HIV and AIDS in the United Kingdom African communities: guidelines produced for prevention and care</li> </ul>							
EUROSURVEILLANCE IN OPEN ACCESS	AM Molesw								
DIRECTORIES Eurosurveillance remains	Health Prot								
in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving	had been r numbers re Canada, Ita In the UK, of nine. Re	eported in main small, aly, Japan, five deaths sults from i	the United Kingdom with 15 cases in F the Netherlands, Po from vCJD were r modelling the incide	n, of which 153 h rance, 4 in Ireland ortugal, Saudi Ara eported in 2005, ence of deaths ir	ave so far resulted d, 2 in the United S abia and Spain [1]* four less than the adicate that the c	previous year's total urrent epidemic wave	<ul> <li>HBV viral load is an independent predictor of progression to hepatocellular carcinoma in chronic HBV patients</li> <li>Erratum for: Euro Surveill 2006;11(1):E060119.1</li> </ul>		
(SHERPA/RoMEO) [2], a	reached a peak of 28 deaths in 2000, and has since declined (Figure). Extrapolating this trend gives an estimate of 2 deaths in the next 12 months (95% prediction interval 0 to 5). With 6					Related articles			

gives an estimate of 2 deaths in the next 12 months (95% prediction interval 0 to 5). With 6

database which uses a

colour-coding scheme to classify publishers according to their selfarchiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a 'green' journal, which means that authors can archive preprint (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

# FIFTH

EUROSURVEILLANCE SCIENTIFIC SEMINAR

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

## TWITTER

Follow Eurosurveillance on Twitter: @Eurosurveillanc

### ZIKA VIRUS INFECTION

Read our articles on Zika virus infection

# EXPRESSION OF CONCERN


Note of concem published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp

# All announcements



patients alive at the end of 2005, however, a prediction of 2 deaths is likely to be an underestimate [2].

Figure. vCJD deaths by year, and fitted quadratic model for incidence trend.



2007 and 2008 ► Fourth case of transfusionassociated vCJD infection in the United Kingdom ► Third case of vCJD reported in the United States

Two cases of variant Creutzfeldt-

Jakob disease reported in Spain in

Second probable case of vCJD in the Netherlands

Evidence of a new human genotype susceptible to variant CJD

It is important to note that, to date, all vCJD cases have been methionine homozygote at codon 129 of the prion protein gene. Preclinical vCJD infection has, however, been reported in a heterozygous patient after blood transfusion from a donor who subsequently developed vCJD [3]. Although the initial epidemic wave is now in decline, it is possible that there will be further epidemics of cases in other genetic groups. There is also the possibility of continuing person to person transmission through certain forms of health care (for instance, in relation to surgery, blood transfusion or treatment with plasma products). It is essential, therefore, to maintain and promote active surveillance of CJD to investigate these possibilities.

This article was adapted by the authors from reference 2

\***Correction**. When this article was published, this sentence was linked to a reference to the website for The European and Allied Countries Collaborative Study Group of CJD (EUROCJD, http://www.eurocjd.ed.ac.uk/EUROINDEX.htm, last updated 2 November 2005). The latest figures have been provided by personal communication with RG Will, National CJD Surveillance Unit, Edinburgh, UK, January 2006. This change was made on Friday 27 January. *Eurosurveillance Editorial Office* 

References:

1. Health Protection Agency. Variant Creutzfeldt-Jakob disease in the United Kingdom and elsewhere:

AND CONTRACT

situation at the end of 2005. CDR Weekly 2006; 16(4): news. (http://www.hpa.org.uk/cdr/index.html)

- Andrews NG. Incidence of variant Creutzfeldt-Jakob disease onsets and deaths in the UK. January 1994 December 2005. Edinburgh: The National Creutzfeldt-Jakob Disease Surveillance Unit; 19 January 2006. (http://www.cjd.ed.ac.uk/vcjdqdec05.htm)
- 3. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. *Lancet* 2004;364:527-9.

	back to top
	1
Back to Table of Contents	
4 Previous	Tweet Next

### To top | NRecommend this page

### The publisher's policy on data collection and use of cookies

**Disclaimer:** The opinions expressed by authors contributing to *Eurosurveillance* do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the *Eurosurveillance* site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the <u>Creative Commons Attribution</u> (<u>CC BY</u>) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurv eillance [ISSN 1560-7917] - ©2007-2016. All rights reserv ed.



This site complies with the <u>HONcode standard for trustworthy health</u> information: verify here.